These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25245321)

  • 1. A two-stage Bayesian method for estimating accuracy and disease prevalence for two dependent dichotomous screening tests when the status of individuals who are negative on both tests is unverified.
    Liu J; Chen F; Yu H; Zeng P; Liu L
    BMC Med Res Methodol; 2014 Sep; 14():110. PubMed ID: 25245321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytic methods for comparing two dichotomous screening or diagnostic tests applied to two populations of differing disease prevalence when individuals negative on both tests are unverified.
    Berry G; Smith CL; Macaskill P; Irwig L
    Stat Med; 2002 Mar; 21(6):853-62. PubMed ID: 11870821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian hierarchical latent class models for estimating diagnostic accuracy.
    Wang C; Lin X; Nelson KP
    Stat Methods Med Res; 2020 Apr; 29(4):1112-1128. PubMed ID: 31146651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian inference on prevalence using a missing-data approach with simulation-based techniques: applications to HIV screening.
    Mendoza-Blanco JR; Tu XM; Iyengar S
    Stat Med; 1996 Oct; 15(20):2161-76. PubMed ID: 8910961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in prevalence of faecal occult blood positivity over time.
    Goulding A; Clark GR; Anderson AS; Strachan JA; Fraser CG; Steele RJ
    J Med Screen; 2019 Dec; 26(4):191-196. PubMed ID: 31364470
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of globally obtained informative priors on bayesian safety performance functions developed for Australian crash data.
    Afghari AP; Haque MM; Washington S; Smyth T
    Accid Anal Prev; 2019 Aug; 129():55-65. PubMed ID: 31108237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hybrid Bayesian hierarchical model combining cohort and case-control studies for meta-analysis of diagnostic tests: Accounting for partial verification bias.
    Ma X; Chen Y; Cole SR; Chu H
    Stat Methods Med Res; 2016 Dec; 25(6):3015-3037. PubMed ID: 24862512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
    Church TR; Ederer F; Mandel JS
    J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy.
    Collins MG; Teo E; Cole SR; Chan CY; McDonald SP; Russ GR; Young GP; Bampton PA; Coates PT
    BMJ; 2012 Jul; 345():e4657. PubMed ID: 22833618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case-control study to evaluate efficacy of screening for faecal occult blood.
    Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
    J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the estimation of disease prevalence by latent class models for screening studies using two screening tests with categorical disease status verified in test positives only.
    Chu H; Zhou Y; Cole SR; Ibrahim JG
    Stat Med; 2010 May; 29(11):1206-18. PubMed ID: 20191614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the interpretation of test sensitivity in the two-test two-population problem: assumptions matter.
    Johnson WO; Gardner IA; Metoyer CN; Branscum AJ
    Prev Vet Med; 2009 Oct; 91(2-4):116-21. PubMed ID: 19651450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening.
    Greenwald B
    Gastroenterol Nurs; 2005; 28(2):90-6. PubMed ID: 15832108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colorectal neoplasias with fecal occult blood tests: false-positive impact of non-dietary restriction.
    Roslani AC; Abdullah T; Arumugam K
    Asian Pac J Cancer Prev; 2012; 13(1):237-41. PubMed ID: 22502676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-stage estimation for screening studies using two diagnostic tests with binary disease status verified in test positives only.
    Li F; Chu H; Nie L
    Stat Methods Med Res; 2015 Dec; 24(6):635-56. PubMed ID: 21920876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Method for Constructing Informative Priors for Bayesian Modeling of Occupational Hygiene Data.
    Quick H; Huynh T; Ramachandran G
    Ann Work Expo Health; 2017 Jan; 61(1):67-75. PubMed ID: 28395307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study.
    Nakama H; Kamijo N; Abdul Fattah AS; Zhang B
    J Med Screen; 1996; 3(2):63-5. PubMed ID: 8849761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.